Dificid (fidaxomicin) / Merck (MSD), Astellas 
Welcome,         Profile    Billing    Logout  
 11 Diseases   2 Trials   2 Trials   1263 News 


«12...4567891011121314...1617»
  • ||||||||||  [VIRTUAL] Impact of an Antimicrobial Intake Process within a Post-acute Medical System () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_939;    
    An antibiotic intake form and process for review for five restricted antibiotics (ceftaroline, ceftazidime/avibactam, ceftolozane/tazobactam, fidaxomicin, meropenem/vaborbactam) was approved at the system ASP committee. Implementation of an antimicrobial intake process within a post-acute medical system resulted in a significant reduction in antibiotic consumption for five targeted antibiotics as well as overall antibiotic expenditure.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    [VIRTUAL] Impact of Antimicrobial Stewardship Interventions on Adherence to Clostridioides difficile Treatment Guidelines () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_937;    
    Our ASP sought to improve adherence to the facility C. difficile infection (CDI) treatment guideline by implementing prospective audit and feedback of CDI cases, changing fidaxomicin from being restricted to Infectious Diseases consult use, to only requiring prospective audit and feedback, and allowing fidaxomicin and oral vancomycin orders only through the order set. A bundle of ASP interventions including prospective audit and feedback of CDI cases improved adherence to facility-specific CDI treatment guidelines.
  • ||||||||||  clarithromycin / Generic mfg.
    Journal:  Direct anti-biofilm effects of macrolides on Acinetobacter baumannii: comprehensive and comparative demonstration by a simple assay using microtiter plate combined with peg-lid. (Pubmed Central) -  Oct 2, 2021   
    In this study, we examined the direct anti-biofilm effects of seven macrolides (azithromycin, clarithromycin, erythromycin, josamycin, spiramycin, fidaxomicin, and ivermectin) on A. baumannii using a simple and newly established in vitro assay system for the swift and serial spectrophotometric determinations of two biofilm-amount indexes of viability and biomass...These results provide insights into possible adjunctive chemotherapy with macrolides for A. baumannii infection. Common five macrolides also interfered with the Agrobacterium tumefaciens NTL(pCF218) (pCF372) bioassay system of N-acyl homoserine lactones, providing insights into sample preparation for the bioassay, and putatively suggesting the actions of macrolides as remote signals in bacterial quorum sensing systems.
  • ||||||||||  Journal:  Navigating changes in Clostridioides difficile prevention and treatment. (Pubmed Central) -  Sep 29, 2021   
    The 2017 Infectious Diseases Society of America (IDSA) guidelines made a significant change in treatment recommendations for first time CDI episodes by recommending the use of oral vancomycin or fidaxomicin in place of metronidazole as a first-line treatment...Treatments currently in phase 3 trials include the antibiotic ridinilazole, the microbiome products SER-109 and RBX2660, and a vaccine...Christine L. Cooper and Ms. Susan Yarbrough have nothing to disclose.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Trial completion:  Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile? (clinicaltrials.gov) -  Sep 9, 2021   
    P=N/A,  N=203, Completed, 
    A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text. Active, not recruiting --> Completed
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Metastatic Melanoma Masquerading as Refractory Diarrhea (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_1708;    
    Metastatic spread to the GI is poor prognostic feature given possibility of obstruction and perforation. Early identification and treatment is critical not only to alleviating symptoms but also to expediting treatment and enhancing long-term outcomes.Figure: Fungating mass in the colon later found to be metastatic melanoma
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Clostridioides difficile Enteritis Resulting in Multisystem Organ Failure: A Fatal Case Report (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_1272;    
    Because of the high morbidity and mortality, consideration should be taken to involve a multidisciplinary approach including medical, surgical, critical care, and palliative care teams. Our case demonstrates that despite these careful treatment efforts, C. diff enteritis remains a life-threatening diagnosis.
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Looking past a Positive Clostridioides difficile Test (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_767;    
    Stool PCR for C. difficile had been positive two months prior and diarrhea persisted despite multiple courses of vancomycin and fidaxomicin...She was discharged home on valganciclovir and seen in clinic six weeks later with complete resolution of her diarrhea...Other causes of colitis should be considered when symptoms persist despite anti-CDI therapies, especially in immunocompromised patients. We present two cases of CMV colitis masquerading as CDI.Figure: Colonic ulceration secondary to CMV colitis
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas, Zinplava (bezlotoxumab) / Merck (MSD)
    Review, Journal:  My Treatment Approach to Clostridioides difficile Infection. (Pubmed Central) -  Aug 18, 2021   
    Standardized microbiota restoration therapies are in clinical development and have completed phase III clinical trials. This review answers common clinical questions in the management of C difficile infection.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Clinical:  Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection. (Pubmed Central) -  Jul 31, 2021   
    We present the case of a patient who developed severe fulminant colitis initially refractory to treatment with oral vancomycin and intravenous metronidazole that had an impressive improvement within 24-hour of starting fidaxomicin...There are few case reports of fulminant CDI treated with fidaxomicin as a salvage therapy for fulminant CDI. In this challenging scenario, information about the use of fidaxomicin is still limited and more clinical trials are needed to support its widespread use.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Journal:  Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia. (Pubmed Central) -  Jul 14, 2021   
    Inhibition of ABCC3 by shRNA-mediated knockdown or with small-molecule inhibitor fidaxomicin, currently used for diarrhea associated with Clostridium difficile infection, effectively resensitized HSC-derived MLL-AML toward standard chemotherapeutic drugs. This study not only functionally established two distinctive origins of human LSCs for MLL-AML and their role in mediating chemoresistance but also identified a potential therapeutic avenue for stem cell-associated treatment resistance by repurposing a well-tolerated antidiarrhea drug already used in the clinic.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Journal:  How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods. (Pubmed Central) -  Jul 7, 2021   
    Now, the cost of new drugs such as fidaxomicin directs us towards alternative treatment options, such as faecal microbiota transplant (FMT)...Our method makes the process flexible and less inconvenient to patients. Long storage time allows a consistent supply of capsules, while small volume and formulation make the procedure tolerable.
  • ||||||||||  Xerava (eravacycline) / SOM Biotech, Ewha Womans University, La Jolla Pharma, PAION
    Preclinical, Journal:  In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. (Pubmed Central) -  Jun 26, 2021   
    This study demonstrated potent in vitro activity of eravacycline against a large collection of clinical C. difficile strains that was not affected by ribotype, susceptibility to vancomycin or the presence of certain tet resistance genes. Further development of eravacycline as an antibiotic to be used in patients with Clostridioides difficile infection is warranted.
  • ||||||||||  Dificid (fidaxomicin) / Merck (MSD), Astellas
    Clinical, Observational data, Journal:  A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France. (Pubmed Central) -  Jun 25, 2021   
    P=N/A
    Further development of eravacycline as an antibiotic to be used in patients with Clostridioides difficile infection is warranted. Fidaxomicin is an effective and well-tolerated CDI treatment in a real-world setting in France, which included patients at high risk of adverse outcomes.Trial registration: Description of the use of fidaxomicin in hospitalised patients with documented Clostridium difficile infection and the management of these patients (DAFNE), NCT02214771, www.ClinicalTrials.gov.